Home About Us Products and Services Healthcare Professionals Non-Healthcare Professionals Guidelines News Contact Us IMAGINE... Frequently Asked Questions Product Support

Latest News

22nd May 2008

Study results confirm T-SPOT^®.TB performance is not affected by low CD4 count in HIV infected subjects

20th February 2008

Study results demonstrate ability of T-SPOT^®.TB to monitor declining response in subjects receiving
anti-TB treatment

29th October 2007

Oxford Immunotec completes $40M financing

09th October 2007

Study results confirm T-SPOT^®.TB is cost-effective in TB control programmes

Oxford Immunotec is developing novel products based on its patented T-SPOT technology, opening new ways to diagnose and monitor infection and disease. The development of our lead product, T‑SPOT.TB is a major advance in the fight against the global resurgence of tuberculosis.